Stock 9939 KINTOR PHARMACEUTICAL LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Kintor Pharmaceutical Limited

Equities

9939

KYG5273B1077

Delayed Hong Kong S.E.
Other stock markets
 04:59:17 08/05/2024 BST 		5-day change 1st Jan Change
1.08 HKD +1.89% Intraday chart for Kintor Pharmaceutical Limited +1.89% -33.74%
04-22 Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint CI
04-22 Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kintor Pharmaceutical Limited Announces Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China Reaches Primary Endpoint
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Kintor Pharmaceutical's Trial of Androgenetic Alopecia Drug Cleared by Chinese Regulator
Kintor Pharmaceutical Limited Announces Phase Ib/III Clinical Trial of KX-826 and Minoxidil Combination Therapy for the Treatment of Men Adults Receives Clearance by China NMPA
Kintor Pharmaceutical Limited Announces Results of Phase III Clinical Trial of KX-826 Topline Treatment for Men Androgenetic Alopecia
Kintor Pharmaceutical Limited Announces the Approval for Phase II Clinical Trial of Hedgehog/SMO Inhibitor GT1708F for Treatment of IPF in China
Kintor Pharmaceutical Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Kintor Pharma Announces Completion of Patient Enrollment in Phase Ii Clinical Trial of Gt20029 for Treatment of Androgenetic Alopecia in China
Kintor Pharmaceutical Limited Announces Completion of First Patient Enrollment in Long-Term Safety Trial of Kx-826
Kintor Pharmaceutical Limited Appoints Ming Ming Cheung as Joint Company Secretary
Kintor Pharmaceutical Limited Announces Successful Completion of Phase II Clinical Trial of KX-826 for Treatment of Androgenetic Alopecia in the US
Kintor Pharmaceutical Limited Announces Successful Completion of Phase I Clinical Trial of GT1708F for Treatment of Hematological Malignancies in China
Kintor Pharmaceutical Limited Announces Completion of First Subject Enrollment in Phase II Clinical Trial of AR-PROTAC (GT20029 ) for Treatment of Men Androgenetic Alopecia in China
Kintor Pharmaceutical Limited Announces Management Changes
Kintor Pharmaceutical Limited Reports Earnings Results for the Full Year Ended December 31, 2022
Kintor Pharma Announces Completion of Subject Enrollment in Phase III Clinical Trial of KX-826 for Treatment of Male Androgenetic Alopecia in China
Kintor Pharma's KX-826 and GT20029 for Treatment of Androgenetic Alopecia and Acne Presented at AAD 2023
Kintor Pharmaceutical Limited Announces Positive Top-line U.S. Phase I Trial Results of GT20029, the World's First Topical Use PROTAC Compound
Kintor Pharmaceutical Limited Announces the Primary Endpoint of Phase II Clinical Study for KX-826's Treatment of Female Androgenetic Alopecia in China Was Met
Kintor Pharmaceutical Limited Announces Top-Line Results of Phase I Clinical Trial of Gt20029 in China
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 9939 Stock
  4. News Kintor Pharmaceutical Limited
  5. Other languages